| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Department of Epidemiology [C. A. H., S. E. H., G. A. C., D. J. H., I. D. V.] and the Harvard Center for Cancer Prevention [C. A. H., D. J. H., I. D. V.], Harvard School of Public Health, Boston, Massachusetts 02115; Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115 [S. E. H., G. A. C., D. J. H., I. D. V.]; and the Department of Preventive Medicine, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California 90089 [C. A. H.]
Among women, the A2 allele of CYP17 has been associated with elevated levels of endogenous steroid hormones; however, it does not seem to be a strong independent risk factor for breast cancer. We assessed the association between the A2 allele of CYP17 and invasive endometrial cancer risk in a case-control study nested within the Nurses’ Health Study cohort (cases: n = 184; controls: n = 554). We also evaluated whether endometrial cancer risk associated with CYP17 genotype was modified by established endometrial cancer risk factors. In addition, we further examined the relationship between CYP17 genotype and endogenous plasma steroid hormone levels among postmenopausal controls not using hormone replacement therapy (HRT). Women with the A2 allele of CYP17 were at decreased risk of endometrial cancer (A1/A1 genotype (reference); A1/A2 genotype: odds ratio, 0.89; 95% confidence interval, 0.62–1.27; A2/A2 genotype: odds ratio, 0.43; 95% confidence interval, 0.23–0.80; P trend, 0.02). We also observed the inverse association between the A2 allele and endometrial cancer risk to be stronger among women with a first-degree family history of endometrial and/or colorectal cancer (P for interaction, 0.05). Among 165 controls, we did not observe women with the A2 allele to have significantly elevated levels of any steroid hormone fraction. When these women were combined and analyzed with those women on whom we had previously examined the relationship between CYP17 genotype and circulating hormone levels (total n = 469), only modest associations were observed for the A2/A2 genotype and steroid hormone fractions estrone (versus A1/A1 genotype: +10.9%; P = 0.05) and estradiol (+8.5%; P = 0.17). These data suggest that the A2 allele of CYP17 decreases endometrial cancer risk, but has only weak effects on endogenous estrogen levels among postmenopausal women.
This article has been cited by other articles:
|
|
 |
|
  V. W. Setiawan, F. R. Schumacher, C. A. Haiman, D. O. Stram, D. Albanes, D. Altshuler, G. Berglund, J. Buring, E. E. Calle, F. Clavel-Chapelon, et al. CYP17 Genetic Variation and Risk of Breast and Prostate Cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2237 - 2246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Campbell, L. Edwards, J. R. McLaughlin, J. Green, H. B. Younghusband, and M. O. Woods Cytochrome P450 17A1 and Catechol O-Methyltransferase Polymorphisms and Age at Lynch Syndrome Colon Cancer Onset in Newfoundland Clin. Cancer Res., July 1, 2007; 13(13): 3783 - 3788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Rebbeck, A. B. Troxel, E. G. Shatalova, R. Blanchard, S. Norman, G. Bunin, A. DeMichele, R. Schinnar, J. A. Berlin, and B. L. Strom Lack of Effect Modification between Estrogen Metabolism Genotypes and Combined Hormone Replacement Therapy in Postmenopausal Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1318 - 1320. [Full Text] [PDF]
|
|
|
|
|
|
T. R. Rebbeck, A. B. Troxel, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, S. Norman, G. Bunin, A. DeMichele, et al. Pairwise Combinations of Estrogen Metabolism Genotypes in Postmenopausal Breast Cancer Etiology Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 444 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Olson, E. V. Bandera, and I. Orlow Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Rebbeck, A. B. Troxel, Y. Wang, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, G. Bunin, A. DeMichele, et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst, September 20, 2006; 98(18): 1311 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Small, M. Marcus, S. L. Sherman, A. K. Sullivan, A. K. Manatunga, and H. S. Feigelson CYP17 genotype predicts serum hormone levels among pre-menopausal women Hum. Reprod., August 1, 2005; 20(8): 2162 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lurie, G. Maskarinec, R. Kaaks, F. Z. Stanczyk, and L. Le Marchand Association of Genetic Polymorphisms with Serum Estrogens Measured Multiple Times During a 2-Year Period in Premenopausal Women Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1521 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Onland-Moret, C. H. van Gils, M. Roest, D. E. Grobbee, and P. H.M. Peeters Cyp17, Urinary Sex Steroid Levels and Breast Cancer Risk in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 815 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Travis, M. Churchman, S. A. Edwards, G. Smith, P. K. Verkasalo, C. R. Wolf, H. Wolf, and T. J. Key No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2282 - 2284. [Full Text] [PDF]
|
|
|
|
|
|
L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Duguay, M. McGrath, J. Lepine, J.-F. Gagne, S. E. Hankinson, G. A. Colditz, D. J. Hunter, M. Plante, B. Tetu, A. Belanger, et al. The Functional UGT1A1 Promoter Polymorphism Decreases Endometrial Cancer Risk Cancer Res., February 1, 2004; 64(3): 1202 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, J. Chubak, E. J. Aiello, C. M. Ulrich, C. Atkinson, J. D. Potter, Y. Yasui, P. L. Stapleton, J. W. Lampe, F. M. Farin, et al. Association of CYP17, CYP19, CYP1B1, and COMT Polymorphisms with Serum and Urinary Sex Hormone Concentrations in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 94 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Association of the CYP17 Gene Polymorphism with the Risk of Prostate Cancer: A Meta-Analysis Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 120 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. De Vivo, G. S. Huggins, S. E. Hankinson, P. J. Lescault, M. Boezen, G. A. Colditz, and D. J. Hunter A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk PNAS, September 17, 2002; 99(19): 12263 - 12268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Haiman, M. J. Stampfer, E. Giovannucci, J. Ma, N. E. Decalo, P. W. Kantoff, and D. J. Hunter The Relationship between a Polymorphism in CYP17 with Plasma Hormone Levels and Prostate Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 743 - 748. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
